Apoptosis: A Potential Therapeutic Approach Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced

[1]  D. Catovsky,et al.  Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice , 1998, British journal of haematology.

[2]  H. Kalthoff,et al.  Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. , 1998, International journal of oncology.

[3]  Guido Kroemer,et al.  Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution , 1997, Cell Death and Differentiation.

[4]  O. Larsson,et al.  Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. , 1997, Glycobiology.

[5]  D. Hedley,et al.  Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. , 1997, Cancer research.

[6]  A. Klippel,et al.  Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.

[7]  S. Sebti,et al.  Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity , 1997, Oncogene.

[8]  G. Evan,et al.  Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis , 1997, Molecular and cellular biology.

[9]  S. Sebti,et al.  Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation* , 1996, The Journal of Biological Chemistry.

[10]  M. Tallman.  Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. , 1996, Leukemia.

[11]  H. Yeger,et al.  HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells , 1996, Nature Medicine.

[12]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  G. Britton,et al.  Structure and properties of carotenoids in relation to function , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Guido Kroemer,et al.  The biochemistry of programmed cell death , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Shaun Parsons,et al.  Improved survival for patients with acute myelogenous leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Law,et al.  Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. , 1994, Biochemical and biophysical research communications.

[17]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[18]  J. Squire,et al.  NUB-7: a stable I-type human neuroblastoma cell line inducible along N- and S-type cell lineages. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  M. Minden,et al.  Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. , 1993, Leukemia.

[20]  Paulo N. Correa,et al.  Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells , 1993 .

[21]  G. Melino,et al.  Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells , 1993, FEBS letters.

[22]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[23]  D. Hunninghake.  HMG CoA reductase inhibitors , 1992 .

[24]  L. M. Luca,et al.  Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. , 1991 .

[25]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[26]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[27]  J. Gibbs.  Ras C-terminal processing enzymes—New drug targets? , 1991, Cell.

[28]  J. Radich,et al.  N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. , 1990, Blood.

[29]  F. McCormick,et al.  N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. , 1990, Blood.

[30]  J. Hoeg.  HMG-CoA reductase inhibitors , 1990 .

[31]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[32]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[33]  M. Minden,et al.  Expression of a retinoic acid receptor gene in myeloid leukemia cells. , 1989, Leukemia.

[34]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[35]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[36]  E. McCulloch,et al.  Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia , 1979 .

[37]  E. C. Beuvery,et al.  Viability measurements of hybridoma cells in suspension cultures , 2006, Cytotechnology.

[38]  J. Spivak,et al.  Commentary on and reprint of Huang M-E, Ye Y-C, Chen S-R, Chai J-R, Lu J-X, Zhoa L, Gu L-J, Wang Z-Y, Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia, in Blood (1988) 72:567–572 , 2000 .

[39]  M. Marcelli,et al.  Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. , 1998, Cancer research.

[40]  L. Cripe.  Adult acute leukemia. , 1997, Current problems in cancer.

[41]  S. Sacchi,et al.  All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). , 1997, Haematologica.

[42]  D. Catovsky,et al.  A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. , 1997, Leukemia & lymphoma.

[43]  S. Orrenius,et al.  Intracellular redox changes during apoptosis. , 1996, Cell death and differentiation.

[44]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.

[45]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.

[46]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.